Epigral Inkomsten in het verleden
Verleden criteriumcontroles 2/6
Epigral has been growing earnings at an average annual rate of 10.8%, while the Chemicals industry saw earnings growing at 15.6% annually. Revenues have been growing at an average rate of 0.7% per year. Epigral's return on equity is 20%, and it has net margins of 11.8%.
Belangrijke informatie
10.8%
Groei van de winst
10.7%
Groei van de winst per aandeel
| Chemicals Groei van de industrie | 17.7% |
| Inkomstengroei | 0.7% |
| Rendement op eigen vermogen | 20.0% |
| Nettomarge | 11.8% |
| Volgende winstupdate | 09 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Epigral Limited's (NSE:EPIGRAL) Shares Leap 29% Yet They're Still Not Telling The Full Story
Jul 04
Epigral Limited (NSE:EPIGRAL) Looks Just Right With A 27% Price Jump
Apr 19Epigral Limited (NSE:EPIGRAL) Soars 28% But It's A Story Of Risk Vs Reward
Feb 23Epigral (NSE:EPIGRAL) Might Be Having Difficulty Using Its Capital Effectively
Feb 21Capital Investment Trends At Meghmani Finechem (NSE:MFL) Look Strong
Apr 05With EPS Growth And More, Meghmani Finechem (NSE:MFL) Makes An Interesting Case
Sep 28Meghmani Finechem's (NSE:MFL) Promising Earnings May Rest On Soft Foundations
May 03Meghmani Finechem Limited's (NSE:MFL) Business Is Yet to Catch Up With Its Share Price
Nov 22Opbrengsten en kosten
Hoe Epigral geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 21,255 | 2,502 | 1,085 | 0 |
| 31 Mar 24 | 19,292 | 1,959 | 1,019 | 0 |
| 31 Dec 23 | 19,667 | 1,953 | 887 | 0 |
| 30 Sep 23 | 20,331 | 2,234 | 871 | 0 |
| 30 Jun 23 | 21,104 | 2,770 | 865 | 0 |
| 31 Mar 23 | 21,884 | 3,533 | 886 | 0 |
| 31 Dec 22 | 21,250 | 3,756 | 924 | 0 |
| 30 Sep 22 | 20,093 | 3,682 | 895 | 0 |
| 30 Jun 22 | 17,934 | 3,236 | 848 | 0 |
| 31 Mar 22 | 15,509 | 2,528 | 768 | 0 |
| 31 Mar 21 | 8,286 | 1,008 | 536 | 0 |
| 31 Mar 20 | 6,098 | 1,141 | 441 | 0 |
| 31 Mar 19 | 7,104 | 1,828 | 482 | 0 |
| 31 Mar 18 | 5,975 | 1,555 | 371 | 0 |
| 31 Mar 17 | 3,921 | 665 | 150 | 0 |
| 31 Mar 16 | 3,982 | 672 | 120 | 0 |
| 31 Mar 15 | 3,518 | 347 | 102 | 0 |
Kwaliteitswinsten: EPIGRAL has high quality earnings.
Groeiende winstmarge: EPIGRAL's current net profit margins (11.8%) are lower than last year (13.1%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: EPIGRAL's earnings have grown by 10.8% per year over the past 5 years.
Versnelling van de groei: EPIGRAL's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: EPIGRAL had negative earnings growth (-9.7%) over the past year, making it difficult to compare to the Chemicals industry average (10.4%).
Rendement op eigen vermogen
Hoge ROE: EPIGRAL's Return on Equity (20%) is considered low.